Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

Vir Biotechnology (VIR) has drawn fresh investor attention after announcing a global collaboration with Astellas around VIR-5500, a dual-masked T-cell engager for metastatic castration-resistant ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...

Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

Vir secured $335 million in upfront and near-term payments from its global collaboration with Astellas to advance VIR-5500.

Astellas and Vir Biotechnology collaborate to advance PSMA-targeting PRO-XTEN dual-masked T-cell engager VIR-5500 to treat prostate cancer: Tokyo Wednesday, February 25, 2026, 09: ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.